BASF India Ltd
BASFBASF India Ltd's earnings have outrun its stock. EPS grew −12.3% in a year against a −24.7% price move.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is in a downtrend (51 weeks in) while the P/E sits at the 13th percentile of its own 6-year range. Underneath, the last four quarters read improving — profit +155.6% year on year, and 73% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
BASF India Ltd trades at ₹3,634, in a downtrend and 51 weeks into that stage. That is −5.2% against its own 200-day average. It sits at 25% of a 52-week range of ₹3,286 to ₹4,688. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks.
Today the stock is in a downtrend — week 51 of stage 4, confirmed. At ₹3,634 it trades −5.2% versus its 200-day average and sits at 25% of its 52-week range (₹3,286–₹4,688).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +369% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
BASF India Ltd trades at 38.1× P/E, near the bottom of its own range — cheaper only 13% of the time. Its long-run median P/E is 50.9×, measured across 5.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 38.1× is near the bottom of its own range — cheaper only 13% of the time, against a long-run median of 50.9× measured over 5.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −12.3% against a −24.7% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +4.8%/yr price move, ~+13.9%/yr came from earnings growth and ~−9.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
BASF India Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 10 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +1.1% | — | — | — |
| Profit | −12.3% | — | — | — |
| EPS | −12.3% | — | — | — |
| Share price | −24.7% | +9.9% | +4.8% | +13.1% |
4-Factor Sector Score
40.7/100 — rank 14 of 20 in Chemicals - Organic · 90% evidence confidence
BASF India Ltd scores 40.7 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 14. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11.9 + 9.3 + 12.2 + 7.3 = 40.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
BASF India Ltd reported ₹3,444 Cr of revenue in the Mar 26 quarter, +4.8% year on year. That is the 2nd straight quarter of year-on-year growth. Over 20 years it has compounded at 16.7% a year. The last full year, FY26, came in at ₹14,944 Cr. The last four reported quarters add to ₹15,078 Cr.
FY26 revenue came in at ₹14,944 Cr (+1.1% on the year), capping 20 years at 16.7% compound. The latest quarter (Mar 26) printed ₹3,444 Cr, +4.8% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +0.1% growth against the decade's 16.7% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −0.4% over the last 4 quarters against +13.8%/yr over the last 8 — rolling over; TTM profit −12.5% vs −28.8%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
BASF India Ltd's operating margin is 3.2% in the Mar 26 quarter, +1.7 percentage points against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 3.7% to 13.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 3.2%, +1.7 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 3.7%–13.0%.
Why the margin moved: operating margin went +1.7 pp year on year while gross margin went +2.4 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
BASF India Ltd earned ₹69.0 Cr of net profit in the Mar 26 quarter, +155.6% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹420 Cr. The 20-year compound rate is 11.8%. That is 2.0% of the quarter's revenue. The same quarter a year earlier earned ₹27.0 Cr.
Mar 26 profit was ₹69.0 Cr, +155.6% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹420 Cr (−12.3%), and the 20-year compound rate is 11.8%.
Why profit moved: revenue contributed +4.8% and the margin +1.7 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +26.0% vs revenue +0.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 73% of BASF India Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹−110 Cr of operating cash against ₹420 Cr of profit. After ₹156 Cr of capital spending, ₹−266 Cr was left as free cash.
FY26: operating cash of ₹−110 Cr against reported profit of ₹420 Cr, leaving free cash of ₹−266 Cr after ₹156 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 73% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 73%: the cash cycle tightened 20 days between FY08 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
BASF India Ltd's cash conversion cycle runs 40 days in FY26, down from 60 days in FY08. Capital spending ran ₹513 Cr over the last 3 years. At FY26 sales of ₹14,944 Cr each day of that cycle holds about ₹40.9 Cr, so roughly ₹1,638 Cr sits inside the business at any moment.
FY26: debtors at 67 days, inventory at 77 days — roughly 2.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 40 days, tighter than FY08's 60.
The full loop: cash goes out to suppliers and production on day 0; stock waits 77 days to sell; customers pay about 67 days after that; and suppliers themselves are paid at 104 days — netting out to the 40-day cycle.
In money terms: at FY26 sales of ₹14,944 Cr, each day of the cycle holds about ₹40.9 Cr — so the 40-day loop keeps roughly ₹1,638 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹513 Cr over the last 3 fiscal years against ₹343 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹160 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
BASF India Ltd earns a ROCE of 15% in FY26. Return on invested capital clears the cost of that capital by +7.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 2.8% net margin on 1.77× asset turns.
FY26 ROCE is 15%.
Why the return is what it is — the wiring (FY26): 2.8% net margin × 1.77× asset turns × 2.13× balance-sheet leverage ≈ 10.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 19.2% − 12.0% = a +7.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
BASF India Ltd carries total debt of ₹133 Cr against shareholder equity of ₹3,957 Cr as of Mar 26, a debt-to-equity of 0.03 — effectively unlevered. On the annual view that ratio went from 0.05 in FY22 to 0.03 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹133 Cr against shareholder equity of ₹3,957 Cr — a debt-to-equity of 0.03. On the annual view, debt-to-equity went from 0.05 (FY22) to 0.03 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of BASF India Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.3 points over the same window, to 6.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +0.9 points over 8 quarters to 5.2%; Domestic institutions: +0.3 points over 8 quarters to 6.3%; Promoters: +0.0 points over 8 quarters to 73.3%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
BASF India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Nitta Gelatin India LtdKERALACHEM | 82.3/100Sector-leading setup78% evidence | 27.8/35 Revenue 11.8% · PAT 34.1% · OPM change 10 pp 83% evidence | 20.2/25 ROCE 31.3% · OPM 28% 76% evidence | 14.3/20 P/E 13.5× · PEG — 50% evidence | 20.0/20 RS sector 71.7% · RS bench 85.7% · 1Y 75.4%4 of 4 weeks ahead to 2026-06-07 100% evidence | |
| Exact sum: 27.8 + 20.2 + 14.3 + 20 = 82.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Balaji Amines LtdBALAMINES | 64.9/100Mixed-positive evidence82% evidence | LEADER | 26.7/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.2/25 ROCE 11% · OPM 25% 76% evidence | 6.6/20 P/E 33.9× · PEG — 50% evidence | 18.4/20 RS sector 27.9% · RS bench 45.8% · 1Y 26.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 13.2 + 6.6 + 18.4 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3OCCL LtdOCCLLTD | 62.1/100Mixed-positive evidence60% evidence | TURNING | 26.2/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.1/25 ROCE 12.8% · OPM 28% 76% evidence | 11.5/20 P/E 10.9× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 46.7% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 26.2 + 12.1 + 11.5 + 12.3 = 62.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Shri Ahimsa Naturals LtdSHRIAHIMSA | 60.8/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 17.8/25 ROCE 21.7% · OPM 28% 95% evidence | 10.3/20 P/E 30.9× · PEG — 15% evidence | 13.8/20 RS sector 22.1% · RS bench 40.5% · 1Y 114.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 17.8 + 10.3 + 13.8 = 60.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Indo Amines LtdINDOAMIN | 59.8/100Mixed-positive evidence77% evidence | TURNING | 22.5/35 Revenue 7.6% · PAT 42.9% · OPM change 2 pp 83% evidence | 16.0/25 ROCE 19.9% · OPM 11% 95% evidence | 13.9/20 P/E 11.7× · PEG — 50% evidence | 7.4/20 RS sector -12.9% · RS bench 0.5% · 1Y -15%10 of 10 weeks ahead 70% evidence |
| Exact sum: 22.5 + 16 + 13.9 + 7.4 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Foseco India LtdFOSECOIND | 57.4/100Mixed-positive evidence83% evidence | TURNING | 18.6/35 Revenue 26.9% · PAT 7.5% · OPM change 2 pp 88% evidence | 14.9/25 ROCE 17.4% · OPM 20% 100% evidence | 11.1/20 P/E 39.7× · PEG 1.31 65% evidence | 12.8/20 RS sector 22.8% · RS bench -2.4% · 1Y 5.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 14.9 + 11.1 + 12.8 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Elantas Beck India LtdELANTAS | 50.5/100Mixed-positive evidence72% evidence | ASLEEP | 17.2/35 Revenue 11.1% · PAT 6.6% · OPM change 0 pp 83% evidence | 17.9/25 ROCE 21.2% · OPM 20% 76% evidence | 7.5/20 P/E 50.9× · PEG — 50% evidence | 7.9/20 RS sector -7.6% · RS bench -2.3% · 1Y -26%1 of 7 weeks ahead 70% evidence |
| Exact sum: 17.2 + 17.9 + 7.5 + 7.9 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Laxmi Organic Industries LtdLXCHEM | 48.2/100Mixed-negative evidence94% evidence | TURNING | 20.8/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.2/25 ROCE 4.7% · OPM 12% 100% evidence | 11.8/20 P/E 39.4× · PEG 1.14 100% evidence | 7.4/20 RS sector -20.5% · RS bench 6.3% · 1Y -13.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 8.2 + 11.8 + 7.4 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Valiant Organics LtdVALIANTORG | 46.9/100Mixed-negative evidence83% evidence | ASLEEP | 23.0/35 Revenue 2.6% · PAT 100% · OPM change 2 pp 83% evidence | 9.6/25 ROCE 5.5% · OPM 12% 95% evidence | 11.4/20 P/E 25.7× · PEG — 50% evidence | 2.9/20 RS sector -18.7% · RS bench -6.3% · 1Y -29.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23 + 9.6 + 11.4 + 2.9 = 46.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.7% and the one-year return is -29.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Shree Ganesh Remedies LtdSGRL | 46.6/100Thin evidence · provisional57% evidence | 11.3/35 Revenue -17.3% · PAT -37.7% · OPM change -4.8 pp 53% evidence | 16.4/25 ROCE 19.2% · OPM 31.9% 57% evidence | 8.9/20 P/E 35.1× · PEG — 50% evidence | 10.0/20 RS sector 2.3% · RS bench -9.9% · 1Y -15.8%4 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 11.3 + 16.4 + 8.9 + 10 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Fairchem Organics LtdFAIRCHEMOR | 44.4/100Mixed-negative evidence87% evidence | BREAKING OUT | 18.4/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 5.7/25 ROCE 3.3% · OPM 10% 95% evidence | 6.0/20 P/E 66.4× · PEG — 50% evidence | 14.3/20 RS sector 1.2% · RS bench 16.6% · 1Y -12.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 5.7 + 6 + 14.3 = 44.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 43.3/100Mixed-negative evidence96% evidence | FADING | 13.8/35 Revenue 4.2% · PAT 1.7% · OPM change 1 pp 88% evidence | 18.0/25 ROCE 21.5% · OPM 21% 100% evidence | 6.0/20 P/E 36.2× · PEG 2.7 100% evidence | 5.5/20 RS sector -10.6% · RS bench 3.4% · 1Y -7.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 18 + 6 + 5.5 = 43.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13GFL LtdGFLLIMITED | 43.0/100Mixed-negative evidence62% evidence | 20.6/35 Revenue 0% · PAT 100% · OPM change 2562 pp 62% evidence | 6.3/25 ROCE 2.1% · OPM 19% 95% evidence | 11.3/20 P/E 11× · PEG — 15% evidence | 4.8/20 RS sector -14.7% · RS bench -16.8% · 1Y -28.6%1 of 8 weeks ahead 70% evidence | |
| Exact sum: 20.6 + 6.3 + 11.3 + 4.8 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14BASF India Ltdthis pageBASF | 40.7/100Mixed-negative evidence90% evidence | ASLEEP | 11.9/35 Revenue -0.4% · PAT -12.5% · OPM change 1.7 pp 88% evidence | 9.3/25 ROCE 14.5% · OPM 3.2% 100% evidence | 12.2/20 P/E 38.1× · PEG 1.62 100% evidence | 7.3/20 RS sector -4.4% · RS bench -8.7% · 1Y -28%1 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 9.3 + 12.2 + 7.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Oriental Aromatics LtdOAL | 38.5/100Mixed-negative evidence74% evidence | TURNING | 13.0/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 7.2/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 231× · PEG — 15% evidence | 9.6/20 RS sector -9.8% · RS bench 15.9% · 1Y -3.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 7.2 + 8.7 + 9.6 = 38.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Gem Aromatics LtdGEMAROMA | 31.4/100Thin evidence · provisional56% evidence | TURNING | 4.3/35 Revenue -27.3% · PAT -80% · OPM change -8.4 pp 83% evidence | 8.6/25 ROCE 3.4% · OPM 14.2% 95% evidence | 8.5/20 P/E 705× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 4.3 + 8.6 + 8.5 + 10 = 31.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sigachi Industries LtdSIGACHI | 25.4/100Adverse evidence77% evidence | TURNING | 6.2/35 Revenue -2.1% · PAT -80% · OPM change -8.8 pp 83% evidence | 6.9/25 ROCE 6.2% · OPM 13.5% 95% evidence | 8.5/20 P/E 30.4× · PEG — 50% evidence | 3.8/20 RS sector -35.5% · RS bench -8.5% · 1Y -33.6%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.2 + 6.9 + 8.5 + 3.8 = 25.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Sacheerome LtdSACHEEROME | 59.9/100Thin evidence · provisional41% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.6/25 ROCE 35.7% · OPM 23% 95% evidence | 10.2/20 P/E 33.3× · PEG — 15% evidence | 11.7/20 RS sector — · RS bench 30.9% · 1Y 141.7%3 of 10 weeks ahead 25% evidence |
| Exact sum: 17.4 + 20.6 + 10.2 + 11.7 = 59.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Jyoti Resins and Adhesives LtdJYOTIRES | 46.1/100Thin evidence · provisional50% evidence | 13.2/35 Revenue 8.7% · PAT -5.5% · OPM change -6 pp 53% evidence | 18.7/25 ROCE 50% · OPM 26% 57% evidence | 10.8/20 P/E 14.3× · PEG — 15% evidence | 3.4/20 RS sector -20.6% · RS bench -30.3% · 1Y -40.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 13.2 + 18.7 + 10.8 + 3.4 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 41.1/100Thin evidence · provisional18% evidence | 14.3/35 Revenue — · PAT -30.4% · OPM change — 18% evidence | 6.8/25 ROCE -2150% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 14.3 + 6.8 + 10 + 10 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is BASF India Ltd's share price today?
BASF India Ltd trades at ₹3,634, −24.7% over the past year. The company is valued at ₹15,729 Cr. The stock sits at 25% of its 52-week range of ₹3,286–₹4,688, −5.2% versus its 200-day average. On the tape, the price is in a downtrend, 51 weeks in. — as of 31 July 2026.
What were BASF India Ltd's latest quarterly results?
BASF India Ltd reported revenue of ₹3,444 Cr and net profit of ₹69.0 Cr for the Mar 26 quarter. Revenue rose 4.8% and profit rose 155.6% year on year. Earnings per share were ₹15.91. The operating margin was 3.2%, 1.7 pp higher than a year earlier. — as of 31 July 2026.
What is BASF India Ltd's revenue?
BASF India Ltd reported revenue of ₹3,444 Cr in the Mar 26 quarter, +4.8% year on year. For the full FY26 fiscal year, revenue was ₹14,944 Cr (+1.1%). Over the last 20 years revenue compounded at 16.7% a year. — as of 31 July 2026.
What is BASF India Ltd's profit?
BASF India Ltd earned ₹69.0 Cr of net profit in the Mar 26 quarter, +155.6% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹420 Cr. The operating margin ran 3.2% in the latest quarter. — as of 31 July 2026.
What is BASF India Ltd's market cap?
BASF India Ltd's market capitalisation is ₹15,729 Cr at a share price of ₹3,634. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is BASF India Ltd's P/E ratio?
BASF India Ltd trades at a P/E of 38.1×, at the 13th percentile of its own 6-year range, against a long-run median of 50.9×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does BASF India Ltd pay a dividend?
Yes — BASF India Ltd's dividend payout was 26% of profit in FY26, and it recorded a payout in each of its last 9 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is BASF India Ltd overvalued?
On its own history, BASF India Ltd looks cheap against its own history: its P/E of 38.1× has been cheaper only 13% of the time in 6 years (long-run median 50.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is BASF India Ltd growing?
Yes — BASF India Ltd is growing: latest-quarter revenue +4.8% year on year, profit +155.6%, and the margin +1.7 pp at 3.2%. The 20-year compound rates are 16.7% (revenue) and 11.8% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is BASF India Ltd performing?
BASF India Ltd is in a downtrend, 51 weeks in. Its latest quarter's revenue rose 4.8% and profit rose 155.6% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is BASF India Ltd in an uptrend?
No — the price is in a downtrend (week 51 of stage 4), trading −5.2% versus its 200-day average and at 25% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is BASF India Ltd beating the market?
On recent form, yes — BASF India Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +369% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will BASF India Ltd's share price go up?
This page publishes no price forecast for BASF India Ltd. What it measures instead: the share price is ₹3,634, the price is in a downtrend 51 weeks in. Its P/E of 38.1× sits at the 13th percentile of its own 6-year range. — as of 31 July 2026.
Who owns BASF India Ltd?
Promoters hold 73.3% of BASF India Ltd, foreign institutions 5.2%, domestic institutions 6.3% and the public 15.2% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does BASF India Ltd have too much debt?
No — BASF India Ltd's debt-to-equity is 0.03, and operating profit covers the interest bill 35×. FY26 borrowings were ₹133 Cr against equity of ₹3,957 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is BASF India Ltd's capex?
BASF India Ltd spent ₹513 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹156 Cr, with ₹160 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is BASF India Ltd's cash flow?
BASF India Ltd generated ₹−110 Cr of operating cash flow in FY26 and ₹−266 Cr of free cash flow after ₹156 Cr of capital spending. Reported profit that year was ₹420 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is BASF India Ltd's profit real cash?
Mostly — over the last 3 fiscal years, 73% of BASF India Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−110 Cr against reported profit of ₹420 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is BASF India Ltd in its business cycle?
BASF India Ltd's FY26 operating margin was 4.4%, against a 9-year band of 3.7%–13.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 3.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the BASF India Ltd story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is BASF India Ltd a stock worth studying right now?
This is not investment advice. The machine read: BASF India Ltd's earnings have outrun its stock. EPS grew −12.3% in a year against a −24.7% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.